JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on IRD stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Debanjana Chatterjee has given his Buy rating due to a combination of factors tied to Opus Genetics’ advancing clinical pipeline and upcoming data catalysts. The ongoing BEST1 Phase 1/2 trial has shown encouraging early safety and efficacy signals, with more comprehensive low‑dose cohort results expected by mid‑2026 that could significantly de‑risk this key program and support robust visual function improvements.
Debanjana Chatterjee’s rating is based on the company’s broader late‑stage momentum and solid financial runway that extends into the first half of 2028. The planned initiation of Phase 3 dosing in the LCA5 trial in the second half of 2026, together with Viatris-partnered POS label‑expansion opportunities and multiple value‑creating milestones through 2026, underpins confidence in Opus Genetics’ ability to create shareholder value, justifying the Buy recommendation and $10 price target.
According to TipRanks, Chatterjee is a 5-star analyst with an average return of 40.5% and a 62.60% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, Tvardi Therapeutics, and Spyre Therapeutics.
In another report released today, Alliance Global Partners also maintained a Buy rating on the stock with a $9.00 price target.